April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Therapeutic trend analysis of normal tension glaucoma cases in common Japanese clinics over a 7-year period
Author Affiliations & Notes
  • Kazuhiko Mori
    Department of Ophthalmology, Kyoto Prefectural Univ of Med, Kyoto, Japan
  • Yoko Ikeda
    Department of Ophthalmology, Kyoto Prefectural Univ of Med, Kyoto, Japan
  • Morio Ueno
    Department of Ophthalmology, Kyoto Prefectural Univ of Med, Kyoto, Japan
  • Kengo Yoshii
    Department of Medical Statistics, Kyoto Prefectural Univ of Med, Kyoto, Japan
  • Shigeru Kinoshita
    Department of Ophthalmology, Kyoto Prefectural Univ of Med, Kyoto, Japan
  • Footnotes
    Commercial Relationships Kazuhiko Mori, Ocular Instruments Inc (P), Santen Pharmaceutical Co (P); Yoko Ikeda, Santen Pharmaceutical Co (P); Morio Ueno, Santen Pharmaceutical Co (P), Senju Pharmaceutical Co (P); Kengo Yoshii, None; Shigeru Kinoshita, Alcon (R), AMO (R), HOYA (R), Otsuka Pharmaceutical Co (C), Santen Pharmaceutical Co (P), Senju Pharmaceutical Co (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 534. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kazuhiko Mori, Yoko Ikeda, Morio Ueno, Kengo Yoshii, Shigeru Kinoshita, Keiji Glaucoma Study Group; Therapeutic trend analysis of normal tension glaucoma cases in common Japanese clinics over a 7-year period. Invest. Ophthalmol. Vis. Sci. 2014;55(13):534.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the therapeutic trend of normal tension glaucoma (NTG) patients in common Japanese clinics over a 7-year period.

Methods: Three respective cross-sectional observational studies were conducted. A total of 3872, 4119, and 8359 eyes of 2176, 2044, and 4491 glaucoma cases who visited 33, 29, and 69 clinics/44, 50, and 97 doctors in the Kyoto and Shiga districts of Japan from January 1 to February 28, in 2006, 2009, and 2013, respectively, were enrolled. In each patient, intraocular pressure (IOP) while under therapy, severity of visual field defect (VF), glaucoma type (NTG with pre-therapeutic high teen IOP number (NTG_hi), NTG with low teen IOP number (NTG_lo), or other), patient age, and therapeutic drug usage were recorded. Of these cases, NTG cases were chosen for the further analysis. Glaucoma severity was divided into 3 stages; i.e., early, intermediate, and end-stage, based on physician evaluation of the patient’s visual field. All doctors were asked to self-declare their subspecialty and were then divided into 2 groups: 1) glaucoma specialists (G group) and 2) general ophthalmologists or specialists other than glaucoma specialists (non-G group). The therapeutic trends of NTG cases were investigated using logistic regression analysis under the parameters of study period, patient age, glaucoma type and stage, IOP, drug usage, and physician subspecialty. Statistical significance was determined as a p-value of >0.05.

Results: The distribution of NTG among all glaucoma types increased from 27.6%, to 36.5%, to 51.4% in the 2006, 2009, and 2013 studies, respectively. Distribution of end-stage NTG also increased from 7.9%, to 9.6%, to 13.0% of all NTG cases. Mean therapeutic IOP of NTG cases decreased from 13.8±2.8, to 13.1±2.6, to 12.9±2.9 mmHg in 2006, 2009, and 2013, respectively. Logistic regression analysis showed that parameters which significantly determined end-stage NTG were study period (odds ratio: 1.156, p<0.05), patient age (1.021, p<0.001), physician subspecialty (odds ratio: 0.957, p<0.001), and the number of drugs used (odds ratio: 1.814, p<0.001), while NTG subtypes or IOP while under therapy showed no significance.

Conclusions: During the 7-year study period, the distribution of the NTG cases, especially the end-stage NTG cases, increased gradually, even though patient IOP was more strictly controlled.

Keywords: 463 clinical (human) or epidemiologic studies: prevalence/incidence • 462 clinical (human) or epidemiologic studies: outcomes/complications  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×